Lia Gore

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

David T. Teachey, Susan R. Rheingold, Shannon L. Maude et al. · Blood · 2013 · 609 citations · Full text

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Arend von Stackelberg, Franco Locatelli, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2016 · 597 citations · Full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

Alex A. Adjei, Roger B. Cohen, Wilbur A. Franklin et al. · Journal of Clinical Oncology · 2008 · 572 citations · Full text

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens et al. · Journal of Clinical Oncology · 2010 · 551 citations · Full text

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 448 citations

Eligibility Criteria, Clinical Endpoint, American Society +16